Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
3.300
-0.020 (-0.60%)
At close: Apr 28, 2026, 4:00 PM EDT
3.260
-0.040 (-1.21%)
After-hours: Apr 28, 2026, 5:09 PM EDT
Biodexa Pharmaceuticals Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 0.38 | 0.7 | 0.58 | |
| Revenue Growth (YoY) | - | - | -45.49% | 20.93% | 68.51% | |
| Cost of Revenue | 3.96 | 5.44 | 4.07 | 5.11 | 4.65 | |
| Gross Profit | -3.96 | -5.44 | -3.69 | -4.41 | -4.08 | |
| Selling, General & Admin | 4.84 | 3.79 | 4.34 | 4.54 | 2.95 | |
| Other Operating Expenses | -0.15 | -0.03 | -0.01 | -0.02 | -0.02 | |
| Operating Expenses | 4.68 | 3.76 | 4.33 | 4.52 | 2.92 | |
| Operating Income | -8.65 | -9.2 | -8.01 | -8.93 | -7 | |
| Interest Expense | -0.23 | -0.17 | -0.04 | -0.05 | -0.04 | |
| Interest & Investment Income | 0.09 | 0.17 | 0.08 | 0.03 | - | |
| Other Non Operating Income (Expenses) | 2.3 | 3.22 | 0.49 | 0.47 | 0.94 | |
| EBT Excluding Unusual Items | -6.49 | -5.98 | -7.49 | -8.49 | -6.11 | |
| Pretax Income | -6.49 | -5.98 | -7.49 | -8.49 | -6.11 | |
| Income Tax Expense | -0.11 | -0.25 | -0.41 | -0.83 | -0.65 | |
| Earnings From Continuing Operations | -6.38 | -5.73 | -7.08 | -7.66 | -5.46 | |
| Net Income | -6.38 | -5.73 | -7.08 | -7.66 | -5.46 | |
| Net Income to Common | -6.38 | -5.73 | -7.08 | -7.66 | -5.46 | |
| Shares Outstanding (Basic) | 0 | - | - | - | - | |
| Shares Outstanding (Diluted) | 0 | - | - | - | - | |
| EPS (Basic) | -58.18 | - | - | - | - | |
| EPS (Diluted) | -58.18 | - | - | - | - | |
| Free Cash Flow | -5.59 | -12.27 | -6.85 | -7.11 | -6.33 | |
| Free Cash Flow Per Share | -50.97 | - | - | - | - | |
| Operating Margin | - | - | -2103.41% | -1277.83% | -1210.73% | |
| Profit Margin | - | - | -1858.01% | -1095.28% | -944.64% | |
| Free Cash Flow Margin | - | - | -1798.42% | -1017.17% | -1094.81% | |
| EBITDA | -8.59 | -9.08 | -7.87 | -8.76 | -6.79 | |
| D&A For EBITDA | 0.05 | 0.12 | 0.14 | 0.17 | 0.21 | |
| EBIT | -8.65 | -9.2 | -8.01 | -8.93 | -7 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.